High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.

"Declarations Ethics approval and consent to participateAll samples were anonymously coded according to the local ethical guidelines as stipulated by the Declaration of Helsinki. Written informed consent was obtained from all the patients, and this study was approved by the Ethics Committee of Chinese PLA General Hospital. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This study was funded by grants from the Start-up Fund for the Introduction of High Level Talents by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The funder played no role in study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication."